KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Change in Inventory (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 13 years of Change in Inventory data on record, last reported at -$2.1 million in Q4 2025.

  • For Q4 2025, Change in Inventory fell 101.78% year-over-year to -$2.1 million; the TTM value through Dec 2025 reached $275.3 million, down 55.58%, while the annual FY2025 figure was $275.3 million, 55.58% down from the prior year.
  • Change in Inventory reached -$2.1 million in Q4 2025 per REGN's latest filing, down from $82.6 million in the prior quarter.
  • Across five years, Change in Inventory topped out at $252.8 million in Q1 2021 and bottomed at -$2.1 million in Q4 2025.
  • Average Change in Inventory over 5 years is $124.5 million, with a median of $117.7 million recorded in 2024.
  • Peak YoY movement for Change in Inventory: soared 257.06% in 2021, then tumbled 101.78% in 2025.
  • A 5-year view of Change in Inventory shows it stood at $252.8 million in 2021, then crashed by 42.92% to $144.3 million in 2022, then tumbled by 67.22% to $47.3 million in 2023, then skyrocketed by 148.84% to $117.7 million in 2024, then crashed by 101.78% to -$2.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Inventory were -$2.1 million in Q4 2025, $82.6 million in Q3 2025, and $42.5 million in Q2 2025.